

DT15 PCT/PTO 02 JUL 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Bednarek, Maria A.

Serial No. To Be Assigned

Filed: On Even Date Herewith

For: SELECTIVE MELANIN-CONCENTRATING HORMONE
TYPE-1 RECEPTOR AGONISTS

Art Unit: _____

Examiner: _____

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.

4. Pursuant to the waiver by the Office of the requirement under 37 CFR 1.98 (a)(2)(i) dated July 11, 2003, if the filing date of this application is after June 30, 2003, copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

EXPRESS MAIL CERTIFICATE
DATE OF DEPOSIT JULY 2 2004
EXPRESS MAIL NO. EY3231531101US
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS
BEING DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE"
ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO
COMMISSIONER FOR PATENTS, P.O. BOX 1450,
ALEXANDRIA, VIRGINIA 22313-1450
MAILED BY Kathy Klutowski
DATE 7-2-04

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

By _____ Date _____

INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

RELATED APPLICATION		
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE

If this is inconvenient, additional copies will be submitted upon request.

6. In accordance with 37 C.F.R. 1.97, (check one)

- ☒ the attached information is filed within three months of the filing date of the captioned case.
- ☐ the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
- ☐ the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action or Notice of Allowance. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- ☐ the undersigned certifies that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ the undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,



By: Sheldon O. Heber

Attorney _____ For Applicant(s)

Reg. No. 38,179

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-1958

Date: July 2 2004

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number

1/500672

Filing Date

First Named Inventor

Bednarek, Maria A.

Group Art Unit

Examiner Name

Sheet

2

of

3

Attorney Docket Number

20954P

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
		Audinot, V. et al. "Structure-Activity Relationship Studies of Melanin-concentrating Hormone (MCH)-related Peptide Ligands at SLC-1, the Human MCH Receptor", The Journal of Biological Chemistry, 2001, Vol. 276, pp. 13554-13562
		Bachner, D. et al. "Identification of melanin concentrating hormone (MCH) as the natural ligand for the orphan somatostatin-like receptor 1 (SLC-1)", FEBS Letters, 1999, Vol. 457, pp. 522-524
		Baker, B. et al. "Structure-Activity Studies With Fragments and Analogues of Salmonid Melanin-Concentrating Hormone", Peptides, 1990, Vol. 11, pp. 1103-1108
		Bednarek, M. et al. "Short Segment of Human Melanin-Concentrating Hormone That Is Sufficient for Full Activation of Human Melanin-Concentrating Hormone Receptors 1 and 2", Biochemistry, 2001, Vol. 40, pp. 9379-9386
		Bednarek, M. et al. "Synthesis and Biological Evaluation in Vitro of a Selective, High Potency Peptide Agonist of Human Melanin-concentrating Hormone Action at Human Melanin-concentrating Hormone Receptor 1", The Journal of Biological Chemistry, 2002, Vol. 277, pp. 13821-13826
		Breton, C. et al. "Isolation and characterization of the human melanin-concentrating hormone gene and a variant gene", Molecular Brain Research, 1993, Vol. 18, pp. 297-310
		Chambers, J. et al. "Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1", Nature, 1999, Vol. 400, pp. 261-265
		Chimania, M. et al. "Predominant GABAB Mediated Dispersion of the Isolated Web Melanophores of the Indian Bull Frog, Rana Tigerina (Daud.)", Indian Journal of Pharmacology, 1995, Vol. 27, pp. 241-244
		Drozdz, R. et al. "(D-(p-Benzoylphenylalanine)13, Tyrosine19)-Melanin-concentrating Hormone, a Potent Analogue for MCH Receptor Crosslinking", Journal of Peptide Science, 1999, Vol. 5, pp. 234-242
		Drozdz, R. et al. "Melanin-concentrating hormone binding to mouse melanoma cells in vitro", FEBS Letters, 1995, Vol. 359, pp. 199-202
		Erickson, J. et al. "Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y", Nature, 1996, Vol. 381, pp. 415-418
		Flier, J. et al. "Obesity and the Hypothalamus: Novel Peptides for New Pathways", Cell, 1998, Vol. 92, pp. 437-440
		Hintermann, E. et al. "Synthesis and Characterization of New Radioligands for the Mammalian Melanin-Concentrating Hormone (MCH) Receptor", Journal of Receptor & Signal Transduction Research, 1999, Vol. 19, pp. 411-422
		Kawauchi, H. et al. "Characterization of melanin-concentrating hormone in chum salmon pituitaries", Nature, 1983, Vol. 305, pp. 321-323
		Knigge, K. et al. "Melanotropic Peptides in the Mammalian Brain: The Melanin-Concentrating Hormone", Peptides, 1996, Vol. 17, pp. 1063-1073

Examiner
SignatureDate
Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449B/PTO			COMPLETE IF KNOWN		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Application Number	0/500672	
			Filing Date		
			First Named Inventor	Bednarek, Maria A.	
			Group Art Unit		
			Examiner Name		
Sheet	3	of	3	Attorney Docket Number	20954P

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
		Lebl, M. et al. "Melanin Concentrating Hormone Analogues: Contraction of the Cyclic Structure. 1. Angonist Activity", Journal of Medicinal Chemistry, 1988, Vol. 31, pp. 949-954
		MacDonald, D. et al. "Molecular Characterization of the Melanin-Concentrating Hormone/Receptor Complex: Identification of Critical Residues Involved in Binding and Activation", Molecular Pharmacology, 2000, Vol. 58, pp. 217-225
		Nahon, J. "The Melanin-Concentrating Hormone: From the Peptide to the Gene", Critical Reviews in Neurobiology, 1994, Vol. 8, pp. 221-262
		Presse, F. et al. "Structure of the Human Melanin Concentrating Hormone mRNA", Molecular Endocrinology, 1990, Vol. 4, pp. 632-637
		Qu, D. et al. "A role for melanin-concentrating hormone in the central regulation of feeding behaviour", Nature, 1996, Vol. 380, pp. 243-247
		Sailer, A. et al. "Identification and characterization of a second melanin-concentrating hormone receptor, MCH-2R", Proc. Natl. Acad. Sci., USA, 2001, Vol. 98, pp. 7564-7569
		Saito, Y. et al. "Molecular characterization of the melanin-concentrating-hormone receptor", Nature, 1999, Vol. 400, pp. 265-269
		Shimada, M. et al. "Mice lacking melanin-concentrating hormone are hypophagic and lean", Nature, 1998, Vol. 396, pp. 670-674
		Shimomura, Y. et al. "Isolation and Identification of Melanin-Concentrating Hormone as the Endogenous Ligand of the SLC-1 Receptor", Biochemical and Biophysical Research Communications, 1999, Vol. 261, pp. 622-626
		Vaughan, J. et al. "Characterization of Melanin-Concentrating Hormone from Rat Hypothalamus", Endocrinology, 1989, Vol. 125, pp. 1660-1665

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003